USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CELDARA MEDICAL, LLC
Address:
16 CAVENDISH CT, CENTERRA RESOURCE PARK, DRTC
LEBANON, NH 03766
Phone:
(617) 320-8521
URL:
EIN:
263282727
DUNS:
828763263
Number of Employees:
11
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,251,551.00 7
SBIR Phase II $5,287,793.00 2

Award List:

Myocardial Infarction Therapeutics

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$199,085.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Myocardial infarction (MI) is the leading cause of death in the developed world, including the United States. Each year over 8.1 million Americans have an MI; 30% die before reaching hospital and 10% die after hospitali zation. The goal of these studies is to… More

TCR-less Targeted T Cells Against Cancer

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$391,529.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This year cancer will become the leading cause of death worldwide. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected to double again, and to triple by 2030. Ideally, any cancer therapy should be effective (at killing cancerous… More

ChNKG2D-Targeted Cellular Cancer Therapy: Preclinical Toxicology

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$413,428.00
Agency:
HHS
Principal Investigator:
Carin M. Sentman
Abstract:
DESCRIPTION (provided by applicant): Cancer is projected to become the leading cause of death worldwide by 2010. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected to double again, and to triple by 2030. Multiple myeloma (MM) is a particularly deadly type of… More

Scleroderma Subtyping from Fresh and Archived Biopsies using NextGen Sequencing

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$535,368.00
Agency:
HHS
Principal Investigator:
Michael W. Fanger – 617-320-8521
Abstract:
DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is an autoimmune disease that presents with a heterogeneous and complex phenotype. Major manifestations of the disease are skin fibrosis, vascular dysfunction, and immune system activation. There are no validated diagnostic markers. There… More

Development of a Novel Anti-Inflammatory Therapeutic Based on Antithrombin

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$747,897.00
Agency:
HHS
Principal Investigator:
Michael W. Fanger – 617-320-8521
Abstract:
DESCRIPTION (provided by applicant): Septic shock is a dire outcome of sepsis, an acute systemic inflammatory state triggered by an infection. In the USA, over 750,000 episodes of sepsis occur each year and mortality reaches 30%. The high prevalence of such devastating outcomes highlights the… More

Depletion of Dendritic Cells by Immunotoxin as Therapy for Myocardial Infarction

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$2,068,342.00
Agency:
HHS
Principal Investigator:
Michael W. Fanger – 617-320-8521
Abstract:
DESCRIPTION (provided by applicant): MI is the leading cause of death in the developed world, including the United States. In 2005 over 8.1 million Americans had an MI; 30% died before reaching hospital and 10% died after hospitalization. It is the 70% whoreach hospital that we believe we can help -… More

ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$3,219,451.00
Agency:
HHS
Principal Investigator:
Michael W. Fanger – 617-320-8521
Abstract:
DESCRIPTION (provided by applicant): The global burden of cancer doubled between 1975 and 2000. Cancer became the leading cause of death worldwide in 2010, and is projected to double again by 2020 and to triple by 2030. This horrible disease has touched each of us, and despite enormous investments… More

Preclinical Development of a Novel Plaque-Regressing Therapy For Atherosclerosis

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$675,944.00
Agency:
HHS
Principal Investigator:
Michael W. Fanger – 617-320-8521
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is the leading cause of death in the world. The staggering mortality rate is expected to increase significantly in the next ten years. In the U.S., an estimated 81 million adults will haveone or more types of cardiovascular disease… More

Combination immunotherapies for the treatment of melanoma

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$288,300.00
Agency:
HHS
Principal Investigator:
Michael W. Fanger – 617-320-8521
Abstract:
DESCRIPTION (provided by applicant): Melanoma is the most common form of cancer in young adults1, and its incidence is rising at a rate higher than any of the seven most common cancers2, increasing 45% between 1992 and 20043. Plexxikon and Roche are codeveloping a BrafV600E inhibitor (i.e.… More